Teva Pharma Announces Executive and Director Changes
Ticker: TEVJF · Form: 8-K · Filed: Nov 12, 2024 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, executive-compensation
Related Tickers: TEVA
TL;DR
Teva Pharma shakes up exec team and board on Nov 5th.
AI Summary
Teva Pharmaceutical Industries Ltd. announced on November 5, 2024, changes in its executive team. The company elected new directors and appointed certain officers, alongside updates to compensatory arrangements for its key executives. These changes are effective as of November 5, 2024.
Why It Matters
Changes in executive leadership and board composition can signal shifts in company strategy, operational focus, or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Registrant
- November 5, 2024 (date) — Date of earliest event reported
- Israel (location) — State or Other Jurisdiction of Incorporation
- 124 Dvora Hanevi’a Street Tel Aviv 6944020 (address) — Address of Principal Executive Offices
FAQ
What specific roles were affected by the executive changes?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not specify the exact roles or individuals involved in this summary.
When were these changes officially reported?
The report was filed as of November 12, 2024, with the earliest event reported on November 5, 2024.
What is Teva Pharmaceutical Industries Ltd.'s primary business?
Teva Pharmaceutical Industries Ltd. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
Where is Teva Pharmaceutical Industries Ltd. headquartered?
The company's principal executive offices are located at 124 Dvora Hanevi’a Street, Tel Aviv 6944020, Israel.
Are there any details on the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not provided in the provided text.
Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2024-11-12 16:30:59
Filing Documents
- d853506d8k.htm (8-K) — 26KB
- 0001193125-24-256014.txt ( ) — 142KB
- teva-20241105.xsd (EX-101.SCH) — 3KB
- teva-20241105_lab.xml (EX-101.LAB) — 17KB
- teva-20241105_pre.xml (EX-101.PRE) — 11KB
- d853506d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: November 12, 2024 By: /s/ Eli Kalif Name: Eli Kalif Title: Executive Vice President, Chief Financial Officer 3